Raymond James Financial Services Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $2.97M | Buy |
10,786
+8,589
| +391% | +$2.36M | ﹤0.01% | 1509 |
|
|
2024
Q2 | $534K | Sell |
2,197
-910
| -29% | -$221K | ﹤0.01% | 2485 |
|
|
2024
Q1 | $464K | Buy |
3,107
+810
| +35% | +$121K | ﹤0.01% | 2571 |
|
|
2023
Q4 | $440K | Sell |
2,297
-41
| -2% | -$7.85K | ﹤0.01% | 2497 |
|
|
2023
Q3 | $414K | Sell |
2,338
-40
| -2% | -$7.08K | ﹤0.01% | 2433 |
|
|
2023
Q2 | $452K | Sell |
2,378
-2,389
| -50% | -$454K | ﹤0.01% | 2399 |
|
|
2023
Q1 | $955K | Sell |
4,767
-380
| -7% | -$76.1K | ﹤0.01% | 1919 |
|
|
2022
Q4 | $1.22M | Sell |
5,147
-1,200
| -19% | -$285K | ﹤0.01% | 1709 |
|
|
2022
Q3 | $1.27M | Sell |
6,347
-5,532
| -47% | -$1.11M | ﹤0.01% | 1684 |
|
|
2022
Q2 | $1.73M | Buy |
11,879
+29
| +0.2% | +$4.23K | ﹤0.01% | 1520 |
|
|
2022
Q1 | $1.94M | Buy |
11,850
+1,017
| +9% | +$166K | ﹤0.01% | 1510 |
|
|
2021
Q4 | $1.84M | Buy |
10,833
+520
| +5% | +$88.2K | ﹤0.01% | 1596 |
|
|
2021
Q3 | $1.95M | Buy |
10,313
+528
| +5% | +$99.7K | ﹤0.01% | 1500 |
|
|
2021
Q2 | $1.66M | Buy |
9,785
+2,583
| +36% | +$438K | ﹤0.01% | 1602 |
|
|
2021
Q1 | $1.02M | Buy |
7,202
+5,292
| +277% | +$747K | ﹤0.01% | 1855 |
|
|
2020
Q4 | $248K | Buy |
1,910
+214
| +13% | +$27.8K | ﹤0.01% | 2572 |
|
|
2020
Q3 | $247K | Buy |
1,696
+19
| +1% | +$2.77K | ﹤0.01% | 2395 |
|
|
2020
Q2 | $248K | Sell |
1,677
-500
| -23% | -$73.9K | ﹤0.01% | 2348 |
|
|
2020
Q1 | $237K | Buy |
2,177
+12
| +0.6% | +$1.31K | ﹤0.01% | 1975 |
|
|
2019
Q4 | $249K | Buy |
+2,165
| New | +$249K | ﹤0.01% | 2434 |
|
|
2018
Q4 | – | Sell |
-8,693
| Closed | -$761K | – | 2547 |
|
|
2018
Q3 | $761K | Buy |
+8,693
| New | +$761K | ﹤0.01% | 1642 |
|